Micot key facts
as of Oct 2026- Developer of a specific peptide new molecular drug based in Xi'an, China.
- Micot is valued at approximately $264.6M as of Oct 2026 (last reported valuation).
- It has raised $100.8M; the latest was Later Stage VC ($13.9M) in Jul 2025.
- Notable investors include SND Ventures Group, Northern Light Venture Capital, Zheshang Venture Capital, Detong Capital, NRL Capital — 12 tracked in total.
- Status: Privately Held (backing).
Micot's last reported valuation, May 2021. Nothing priced has surfaced since.
- ·The complete investor list: 12 names
- ·Watch Micot: the Monday email on marks, rounds and moves
Micot funding rounds
No funding rounds for Micot are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Micot
12+Micot valuation
Micot's last reported valuation was $265 million in May 2021. No priced round, secondary trade or fund mark has surfaced since.
Micot investors
12 investors are on record for Micot, including SND Ventures Group, Northern Light Venture Capital, Zheshang Venture Capital and Detong Capital.
About Micot
Developer of a specific peptide new molecular drug based in Xi'an, China. The company focuses on the clinical research and development of innovative biopharmaceuticals, vaccines and biomolecular drug delivery systems and products, enabling clients to effectively provide medical solutions to major diseases and improve treatment efficiency.
- Sector
- Healthcare
- HQ
- Xi'an, China
- Founded
- 2007
- Employees
- 39
- Website
- micot.cn/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.